Eleven Biotherapeutics (EBIO) Reports Q4 Loss of $0.15/Share

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q4 EPS of ($0.15), versus ($0.53) reported last year. Revenue for the quarter came in at $825 thousand, versus $565 thousand reported last year.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Benchmark Reiterates Buy Rating on Malibu Boats (MBUU) on Significant Earnings Upside
• BW LPG Limited (BWLP) Reports Q1 EPS of $0.79